Jasper Therapeutics Faces Class Action Lawsuit Over Misleading Statements.

viernes, 7 de noviembre de 2025, 3:40 am ET1 min de lectura
ATYR--
JSPR--

Jasper Therapeutics is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934. The lawsuit claims the company made false and misleading statements about its manufacturing controls and clinical trials. Shareholders who purchased JSPR shares during the class period (Nov 30, 2023 - Jul 3, 2025) are encouraged to contact the DJS Law Group regarding possible lead plaintiff appointments. The deadline for appointment is Nov 18, 2025.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios